Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212 489 2100

Fax: 212 489 2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, Queensbury, United States

Playthegame06 Mar. 31 at 2:22 AM

$DCTH

1 · Reply

alexpitti Mar. 30 at 9:25 PM

guys follow me. i'm back on twitter $DCTH $STXS $RCEL $ABEO $PROF https://x.com/alex__pitti

0 · Reply

alexpitti Mar. 30 at 4:10 PM

$DCTH we should get a pre announcement mid next week if we are going to get one remember, monday is my birthday. mark it down

1 · Reply

zanecarr85 Mar. 30 at 12:32 PM

$DCTH biotech runner type behavior possible here but needs real volume ignition not just chat room noise

0 · Reply

brunoq14 Mar. 30 at 12:11 PM

$DCTH IMCR is also doing poorly in this market. Some brokerages are all in on IDYA (Truist and Cantor), with $60 target prices.

0 · Reply

DragonAlgo Mar. 30 at 10:57 AM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-04-17 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $1.93 Stop: $1.39 TP1: $2.51 TP2: $3.28 TP3: $4.63 🔗 https://dragonalgo.com

0 · Reply

brunoq14 Mar. 30 at 10:18 AM

$DCTH Well, we have the CHOPIN results and the advancing Phase 2 trials, but no evidence so far that the market attaches any value to these factors. Granted that the current risk off market is not friendly to small cap stocks.

0 · Reply

alexpitti Mar. 27 at 12:18 AM

$DCTH we should be 2 weeks away from a preannouncement

0 · Reply

Playthegame06 Mar. 26 at 2:10 AM

$DCTH There’s too much risk for small caps. Fear of recession on the horizon.

0 · Reply

alexpitti Mar. 24 at 10:31 PM

$DCTH you can say that for today. Algos hate the guidance

0 · Reply

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Mar 2, 2026, 3:42 PM EST - 4 weeks ago

Delcath: Fundamentals Intact, Despite Share Price Weakness

Feb 26, 2026, 3:17 PM EST - 4 weeks ago

Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 8:00 AM EST - 4 weeks ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 8:00 AM EST - 6 weeks ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Jan 27, 2026, 8:05 AM EST - 2 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 21, 2026, 4:01 PM EST - 2 months ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2026, 12:22 PM EST - 2 months ago

Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade

Jan 9, 2026, 8:05 AM EST - 2 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Dec 31, 2025, 8:00 AM EST - 3 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 4 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Nov 20, 2025, 4:01 PM EST - 4 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 18, 2025, 8:00 AM EST - 4 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 13, 2025, 8:30 AM EST - 4 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 6, 2025, 4:01 PM EST - 5 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 6, 2025, 2:15 PM EST - 5 months ago

Delcath: Temporary Headwinds Are No Cause For Concern

Nov 4, 2025, 5:16 PM EST - 5 months ago

Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 5 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Oct 21, 2025, 8:30 AM EDT - 5 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 20, 2025, 5:05 PM EDT - 5 months ago

Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript

Oct 20, 2025, 3:06 PM EDT - 5 months ago

Delcath: Large Upside With Limited Downside Risk

Oct 18, 2025, 4:15 PM EDT - 5 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:13 PM EDT - 5 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Sep 22, 2025, 4:01 PM EDT - 6 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Aug 19, 2025, 8:30 AM EDT - 8 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 6, 2025, 3:06 PM EDT - 8 months ago

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 8:00 AM EDT - 8 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 8 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 23, 2025, 4:01 PM EDT - 8 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jun 12, 2025, 8:36 AM EDT - 10 months ago

Delcath Systems: Growing Fast, But Business Model Is Fragile

May 22, 2025, 7:00 AM EDT - 11 months ago

Delcath Systems Issues Full Year 2025 Guidance

May 18, 2025, 8:25 AM EDT - 11 months ago

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

May 15, 2025, 4:30 PM EDT - 11 months ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 11 months ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 10:55 AM EDT - 11 months ago

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 11 months ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 2, 2025, 11:49 AM EDT - 1 year ago

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 2:17 PM EST - 1 year ago

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Playthegame06 Mar. 31 at 2:22 AM

$DCTH

1 · Reply

alexpitti Mar. 30 at 9:25 PM

guys follow me. i'm back on twitter $DCTH $STXS $RCEL $ABEO $PROF https://x.com/alex__pitti

0 · Reply

alexpitti Mar. 30 at 4:10 PM

$DCTH we should get a pre announcement mid next week if we are going to get one remember, monday is my birthday. mark it down

1 · Reply

zanecarr85 Mar. 30 at 12:32 PM

$DCTH biotech runner type behavior possible here but needs real volume ignition not just chat room noise

0 · Reply

brunoq14 Mar. 30 at 12:11 PM

$DCTH IMCR is also doing poorly in this market. Some brokerages are all in on IDYA (Truist and Cantor), with $60 target prices.

0 · Reply

DragonAlgo Mar. 30 at 10:57 AM

0 · Reply

brunoq14 Mar. 30 at 10:18 AM

0 · Reply

alexpitti Mar. 27 at 12:18 AM

$DCTH we should be 2 weeks away from a preannouncement

0 · Reply

Playthegame06 Mar. 26 at 2:10 AM

$DCTH There’s too much risk for small caps. Fear of recession on the horizon.

0 · Reply

alexpitti Mar. 24 at 10:31 PM

$DCTH you can say that for today. Algos hate the guidance

0 · Reply

mar99 Mar. 23 at 8:01 PM

$DCTH Quite a pathetic performance today. Got hammered last week when the market dropped but big up market it does nothing aside from recovering from the crazy drop to 8.90 this morning. Very weak stock. They just love taking it down.

1 · Reply

alexpitti Mar. 23 at 5:56 PM

$DCTH the good news is now the ideaya data is coming in late April, so if delcath wants to preannounce on april 10th, they can do so and get a small bounce

1 · Reply

brunoq14 Mar. 23 at 3:32 AM

$DCTH https://investors.delcath.com/node/18961/html. 13G. Daniel Kaufman 5.08%

1 · Reply

alexpitti Mar. 22 at 11:53 PM

I lied. $DCTH the ideaya data lock is now in 1h april. woops

0 · Reply

alexpitti Mar. 22 at 10:23 PM

$DCTH looks like it could be a rough week for delcath. hope we get through it

1 · Reply

alexpitti Mar. 21 at 12:46 AM

$DCTH the ideaya data for their phase 3 PFS data on 130 patients with mUM is very likely coming next week

1 · Reply

alexpitti Mar. 20 at 4:35 PM

$DCTH april can't come soon enough, but delcath hates higher rates

0 · Reply

DragonAlgo Mar. 20 at 4:48 AM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-03-20 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $0.07 Stop: $0.05 TP1: $0.09 TP2: $0.12 TP3: $0.17 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

alexpitti Mar. 20 at 12:20 AM

$DCTH there's this thing called nuclear war. And also a thing called conservative guidance which will likely be partially reversed in april with a solid beat

1 · Reply

arcuy Mar. 19 at 9:04 AM

$DCTH why such a discount on the price ?

2 · Reply

brunoq14 Mar. 19 at 1:46 AM

$DCTH Another REMS site. Is that #29? Oregon Health & Science University Hospital

1 · Reply

alexpitti Mar. 18 at 6:47 PM

sometimes these stocks have a little bump in the road and fall. and then some macro issue just exacerbates the selling to no end $DCTH $ABEO $STXS

1 · Reply

Market Cap	311.67M
Revenue (ttm)	85.23M
Net Income (ttm)	2.70M
EPS (ttm)	N/A
PE Ratio	130.43
Forward PE	N/A
Profit Margin	3.17%
Debt to Equity Ratio	0.00

Volume	152,655
Avg Vol	468,436
Day's Range	N/A - N/A
Shares Out	34.75M
Stochastic %K	12%
Beta	0.38
Analysts	Strong Sell
Price Target	$22.17